A glucagon-like peptide receptor 1 (GLP-1R) agonist inhibits the conversion of astrocytes into a neurotoxic phenotype and protects against neurodegeneration, shedding light on the pathogenesis of Parkinson’s disease.
This is a preview of subscription content, log in via an institution to check access.
Marina Spence/Springer Nature
References
Poewe, W. et al. Nat. Rev. Dis. Prim. 3, 17013 (2017).
Lindqvist, D. et al. Brain Behav. Immun. 33, 183–189 (2013).
Yun, S.P. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0051-5 (2018).
Athauda, D. & Foltynie, T. Drug Discov. Today 21, 802–818 (2016).
Aviles-Olmos, I. et al. J. Clin. Invest. 123, 2730–2736 (2013).
Aviles-Olmos, I. et al. J. Parkinsons Dis. 4, 337–344 (2014).
Athauda, D. et al. Lancet 390, 1664–1675 (2017).
Athauda, D. et al. J. Parkinsons Dis. 8, 247-258 (2018).
De Pablo-Fernandez, E. et al. Neurology (in the press).
Ransohoff, R. M. Science 353, 777–783 (2016).
Witoelar, A. et al. JAMA Neurol. 74, 780–792 (2017).
Liddelow, S. A. et al. Nature 541, 481–487 (2017).
Miller, A. H. & Raison, C. L. Nat. Rev. Immunol. 16, 22–34 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Brundin, L., Bergkvist, L. & Brundin, P. Fire prevention in the Parkinson’s disease brain. Nat Med 24, 900–902 (2018). https://doi.org/10.1038/s41591-018-0109-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0109-4
- Springer Nature America, Inc.